10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 9 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
Vadimezan (ASA404) Vadimezan (ASA404, NSC 640488, DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a STING agonist w
In vitro
In DLD-1 human colon carcinoma cells, DMXAA inhibits DT-diaphorase activity without significant effects on the activity of cytochrome b5 reductase and cytochrome P450 reductase. Combination of menadione and DMXAA leads to an increase in the antiproliferative activity of DLD-1 cells. DMXAA, as an antiviral agent, inhibits VSV-induced cytotoxicity and influenza virus replication in RAW 264.7 macrophages. A recent study shows that DMXAA has non-immune-mediated inhibitory effects against several kinase members of VEGFR (vascular endothelial growth factor receptor), such as VEGFR2 signalling in human umbilical vein endothelial cells.
In vivo
DMXAA treatment significantly protects C57BL/6J mice infected i.n. with 200 p.f.u. mouse-adapted H1N1 influenza PR8 virus with 60% survival, while the control group only exhibited 20% survival. DMXAA significantly delays tumor growth induced by chemical carcinogen, increases the time to tumor doubling and increases time from treatment to euthanasia. After the treatment of DMXAA, median tumor doubling time, median tumour tripling time and median time from treatment to euthanasia in tumor-bearing animals are increased by approximately 4.4-, 1.8- and 2.7-fold, respectively.
Cell Data
cell lines：HT-29 cells
Concentrations：0-2 mM
Incubation Time：96 hours
Powder Purity:≥99%
| Isomeric SMILES | CC1=C(C2=C(C=C1)C(=O)C3=CC=CC(=C3O2)CC(=O)O)C |
|---|---|
| WGK Germany | 3 |
| RTECS | ZD5536200 |
| Molecular Weight | 282.29 |
| Reaxy-Rn | 4262852 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=4262852&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubility | Solubility (25°C) In vitro DMSO: 100 mg/mL (164.83 mM); Water: 100 mg/mL (164.83 mM); Ethanol: Insoluble; |
|---|---|
| Melt Point(°C) | 264 °C |
| 1. Xue Wang, Lu Liu, Yingying Chen, Lirui Jia, Yongjun Wang, Wei Jing, Guangqi Yan. (2025) MgZnFe-layered double hydroxides as a dual-function platform for enhancing subunit vaccine efficacy in tumor immunotherapy. International Journal of Pharmaceutics-X, [PMID:40978011] [10.1016/j.ijpx.2025.100384] |
| 2. Qi Long, Yuliang Yang, Fangling Liao, Haoting Chen, Dongyue He, Shengliang Li, Li Pengcheng, Weisheng Guo, Yafang Xiao. (2023) NIR-II Fluorescence and PA Imaging Guided Activation of STING Pathway in Photothermal Therapy for Boosting Cancer Immunotherapy by Theranostic Thermosensitive Liposomes. Journal of Materials Chemistry B, [PMID:37608753] [10.1039/D3TB00711A] |
| 3. Yixuan Liu, Qi Sun, Chengfei Zhang, Min Ding, Cheng Wang, Qian Zheng, Zhijie Ma, Haojun Xu, Guoren Zhou, Xiaoming Wang, Zhangjun Cheng, Hongping Xia. (2023) STING-IRG1 inhibits liver metastasis of colorectal cancer by regulating the polarization of tumor-associated macrophages. iScience, [PMID:37554436] [10.1016/j.isci.2023.107376] |
| 4. Yuan-Fu Ding, Ziyi Wang, Cheryl H.T. Kwong, Yonghua Zhao, Greta S.P. Mok, Hua-Zhong Yu, Ruibing Wang. (2023) Platelet-mimicking supramolecular nanomedicine with precisely integrated prodrugs for cascade amplification of synergistic chemotherapy. JOURNAL OF CONTROLLED RELEASE, [PMID:37331605] [10.1016/j.jconrel.2023.06.015] |
| 5. Weixin Li, Zhuqi Huang, Yue Luo, Yaqian Cui, Mingjiang Xu, Wu Luo, Gaojun Wu, Guang Liang. (2023) Tetrandrine alleviates atherosclerosis via inhibition of STING-TBK1 pathway and inflammation in macrophages. INTERNATIONAL IMMUNOPHARMACOLOGY, [PMID:37099944] [10.1016/j.intimp.2023.110139] |
| 6. Jia Liu, Zuoyu Chen, Lixue Deng, Chundong Yao, Zhixin Zhou, Cheng Zhou, Yawen Bin, Miaodeng Liu, Liping Wang, Lin Wang, Zheng Wang. (2025) Metal-phenolic networks specifically eliminate hypoxic tumors by instigating oxidative and proteotoxic stresses. Bioactive Materials, [PMID:40026824] [10.1016/j.bioactmat.2025.01.022] |
| 7. Lirui Jia, Yang Qin, Xin Li, Hongzhuo Liu, Zhonggui He, Yongjun Wang. (2025) STING-activating layered double hydroxide nano-adjuvants for enhanced cancer immunotherapy. BIOMATERIALS, [PMID:40164041] [10.1016/j.biomaterials.2025.123294] |
| 8. Yu-Zhang Wang, Wei-Hai Chen, Zi-Yi Han, Shi-Man Zhang, Ping Ji, Cheng Zhang, Jun-Long Liang, Xian-Zheng Zhang. (2025) Targeted tumor therapy with L-cyst(e)ine-addicted bacteria-nanodrug biohybrids. Cell Metabolism, [PMID:40215982] [10.1016/j.cmet.2025.03.012] |
| 9. Zhanxue Xu, Xinrui Yang, Xingyu Lu, Dandan Su, Yidan Wang, Huixing Wu, Zhenhua Zhang, Changrui Long, Liqian Su, Yanyu Wang, Hongbo Chen, Shijian Xiang, Benjie Zhou. (2025) PD-L1 Antibody-Modified Plant-Derived Nanovesicles Carrying a STING Agonist for the Combinational Immunotherapy of Melanoma. BIOMATERIALS, [PMID:40367814] [10.1016/j.biomaterials.2025.123396] |
